New multitarget directed benzimidazole‐2‐thiol‐based heterocycles as prospective anti‐radical and anti‐Alzheimer 's agents
A series of new heterocycles ( 4 – 18 ) was synthesized by the structural modification of benzimidazole‐2‐thiol (BT, 2‐MBI). The structures of the synthesized compounds were confirmed with the help of high‐resolution mass spectrometry (HRMS) and 1 HNMR spectroscopy. High inhibitions of the oxidants...
Gespeichert in:
| Veröffentlicht in: | Drug development research 2021-04, Vol.82 (2), p.207-216 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 216 |
|---|---|
| container_issue | 2 |
| container_start_page | 207 |
| container_title | Drug development research |
| container_volume | 82 |
| creator | Latif, Abdul Bibi, Samina Ali, Sardar Ammara, Ammara Ahmad, Manzoor Khan, Ajmal Al‐Harrasi, Ahmed Ullah, Farhat Ali, Mumtaz |
| description | A series of new heterocycles (
4
–
18
) was synthesized by the structural modification of benzimidazole‐2‐thiol (BT, 2‐MBI). The structures of the synthesized compounds were confirmed with the help of high‐resolution mass spectrometry (HRMS) and
1
HNMR spectroscopy. High inhibitions of the oxidants such as ABTS and DPPH were observed for compounds
9
[IC
50
(s) = 167.4 μM (ABTS), 139.5 μM (DPPH)],
10
[IC
50
(s) = 186.5 μM (ABTS), 155.4 μM (DPPH)],
11
[IC
50
(s) = 286.1 μM (ABTS), 189.1 μM (DPPH)],
12
[IC
50
(s) = 310.8 μM (ABTS), 162.2 μM (DPPH)],
14
[IC
50
(s) = 281.3 μM (ABTS), 205.7 μM (DPPH)],
15
[IC
50
(s) = 284.1 μM (ABTS), 177.3 μM (DPPH)], and
16
[IC
50
(s) = 344.7 μM (ABTS), 270.2 μM (DPPH)] as compared with Ascorbic acid [IC
50
(s) = 340.9 μM (ABTS), 164.3 μM (DPPH)]. The anti‐Alzheimer's activity was performed in vitro against cholinesterase enzymes (AChE, BChE). Compound
11
was able to show significant inhibitions [IC
50
(s) = 121.2 μM (AChE), 38.3 μM (BChE)] as against that of galantamine [IC
50
(s) = 139.4 μM (AChE), 40.3 μM (BChE)]. Compound
14
was found as a very good inhibitor of butyrylcholinesterase (IC
50
= 35.4 μM) as compared with standard galantamine. Molecular docking was further performed to investigate the mechanism of anticholinesterase activity. |
| doi_str_mv | 10.1002/ddr.21740 |
| format | Article |
| fullrecord | <record><control><sourceid>crossref</sourceid><recordid>TN_cdi_crossref_primary_10_1002_ddr_21740</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_1002_ddr_21740</sourcerecordid><originalsourceid>FETCH-LOGICAL-c740-e02e009ef33fb51530d048bb906eb9dc1ce02a7e0539bd3c1419698e462856a73</originalsourceid><addsrcrecordid>eNo1kLtOAzEQRS0EEiFQ8AfuEMWGsb0vl1HES4qgSb_yYzZrtJuNbANKKgo-gG_kSzCvYnQ1o3tHM4eQcwYzBsCvrPUzzqocDsiEgawzzqU8JBPgFc9yIdkxOQnhCYCxvK4n5P0BX-nw3EcXlV9jpNZ5NBEt1bjZu8FZtR97_Hz74Kli58Y-qVYhOTqM6EezMz0GqgLd-jFsU9i9IFWb6JLRK-uM6lNr_0fzft-hG9DTi5Ra4yaGU3LUqj7g2Z9OyermerW4y5aPt_eL-TIz6aEMgSOAxFaIVhesEGAhr7WWUKKW1jCTHKpCKITUVhiWM1nKGvOS10WpKjEll79rTTo0eGybrXeD8ruGQfNNr0n0mh964gstPGoY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>New multitarget directed benzimidazole‐2‐thiol‐based heterocycles as prospective anti‐radical and anti‐Alzheimer 's agents</title><source>Wiley Online Library All Journals</source><creator>Latif, Abdul ; Bibi, Samina ; Ali, Sardar ; Ammara, Ammara ; Ahmad, Manzoor ; Khan, Ajmal ; Al‐Harrasi, Ahmed ; Ullah, Farhat ; Ali, Mumtaz</creator><creatorcontrib>Latif, Abdul ; Bibi, Samina ; Ali, Sardar ; Ammara, Ammara ; Ahmad, Manzoor ; Khan, Ajmal ; Al‐Harrasi, Ahmed ; Ullah, Farhat ; Ali, Mumtaz</creatorcontrib><description>A series of new heterocycles (
4
–
18
) was synthesized by the structural modification of benzimidazole‐2‐thiol (BT, 2‐MBI). The structures of the synthesized compounds were confirmed with the help of high‐resolution mass spectrometry (HRMS) and
1
HNMR spectroscopy. High inhibitions of the oxidants such as ABTS and DPPH were observed for compounds
9
[IC
50
(s) = 167.4 μM (ABTS), 139.5 μM (DPPH)],
10
[IC
50
(s) = 186.5 μM (ABTS), 155.4 μM (DPPH)],
11
[IC
50
(s) = 286.1 μM (ABTS), 189.1 μM (DPPH)],
12
[IC
50
(s) = 310.8 μM (ABTS), 162.2 μM (DPPH)],
14
[IC
50
(s) = 281.3 μM (ABTS), 205.7 μM (DPPH)],
15
[IC
50
(s) = 284.1 μM (ABTS), 177.3 μM (DPPH)], and
16
[IC
50
(s) = 344.7 μM (ABTS), 270.2 μM (DPPH)] as compared with Ascorbic acid [IC
50
(s) = 340.9 μM (ABTS), 164.3 μM (DPPH)]. The anti‐Alzheimer's activity was performed in vitro against cholinesterase enzymes (AChE, BChE). Compound
11
was able to show significant inhibitions [IC
50
(s) = 121.2 μM (AChE), 38.3 μM (BChE)] as against that of galantamine [IC
50
(s) = 139.4 μM (AChE), 40.3 μM (BChE)]. Compound
14
was found as a very good inhibitor of butyrylcholinesterase (IC
50
= 35.4 μM) as compared with standard galantamine. Molecular docking was further performed to investigate the mechanism of anticholinesterase activity.</description><identifier>ISSN: 0272-4391</identifier><identifier>EISSN: 1098-2299</identifier><identifier>DOI: 10.1002/ddr.21740</identifier><language>eng</language><ispartof>Drug development research, 2021-04, Vol.82 (2), p.207-216</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c740-e02e009ef33fb51530d048bb906eb9dc1ce02a7e0539bd3c1419698e462856a73</citedby><cites>FETCH-LOGICAL-c740-e02e009ef33fb51530d048bb906eb9dc1ce02a7e0539bd3c1419698e462856a73</cites><orcidid>0000-0002-3329-4039</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids></links><search><creatorcontrib>Latif, Abdul</creatorcontrib><creatorcontrib>Bibi, Samina</creatorcontrib><creatorcontrib>Ali, Sardar</creatorcontrib><creatorcontrib>Ammara, Ammara</creatorcontrib><creatorcontrib>Ahmad, Manzoor</creatorcontrib><creatorcontrib>Khan, Ajmal</creatorcontrib><creatorcontrib>Al‐Harrasi, Ahmed</creatorcontrib><creatorcontrib>Ullah, Farhat</creatorcontrib><creatorcontrib>Ali, Mumtaz</creatorcontrib><title>New multitarget directed benzimidazole‐2‐thiol‐based heterocycles as prospective anti‐radical and anti‐Alzheimer 's agents</title><title>Drug development research</title><description>A series of new heterocycles (
4
–
18
) was synthesized by the structural modification of benzimidazole‐2‐thiol (BT, 2‐MBI). The structures of the synthesized compounds were confirmed with the help of high‐resolution mass spectrometry (HRMS) and
1
HNMR spectroscopy. High inhibitions of the oxidants such as ABTS and DPPH were observed for compounds
9
[IC
50
(s) = 167.4 μM (ABTS), 139.5 μM (DPPH)],
10
[IC
50
(s) = 186.5 μM (ABTS), 155.4 μM (DPPH)],
11
[IC
50
(s) = 286.1 μM (ABTS), 189.1 μM (DPPH)],
12
[IC
50
(s) = 310.8 μM (ABTS), 162.2 μM (DPPH)],
14
[IC
50
(s) = 281.3 μM (ABTS), 205.7 μM (DPPH)],
15
[IC
50
(s) = 284.1 μM (ABTS), 177.3 μM (DPPH)], and
16
[IC
50
(s) = 344.7 μM (ABTS), 270.2 μM (DPPH)] as compared with Ascorbic acid [IC
50
(s) = 340.9 μM (ABTS), 164.3 μM (DPPH)]. The anti‐Alzheimer's activity was performed in vitro against cholinesterase enzymes (AChE, BChE). Compound
11
was able to show significant inhibitions [IC
50
(s) = 121.2 μM (AChE), 38.3 μM (BChE)] as against that of galantamine [IC
50
(s) = 139.4 μM (AChE), 40.3 μM (BChE)]. Compound
14
was found as a very good inhibitor of butyrylcholinesterase (IC
50
= 35.4 μM) as compared with standard galantamine. Molecular docking was further performed to investigate the mechanism of anticholinesterase activity.</description><issn>0272-4391</issn><issn>1098-2299</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNo1kLtOAzEQRS0EEiFQ8AfuEMWGsb0vl1HES4qgSb_yYzZrtJuNbANKKgo-gG_kSzCvYnQ1o3tHM4eQcwYzBsCvrPUzzqocDsiEgawzzqU8JBPgFc9yIdkxOQnhCYCxvK4n5P0BX-nw3EcXlV9jpNZ5NBEt1bjZu8FZtR97_Hz74Kli58Y-qVYhOTqM6EezMz0GqgLd-jFsU9i9IFWb6JLRK-uM6lNr_0fzft-hG9DTi5Ra4yaGU3LUqj7g2Z9OyermerW4y5aPt_eL-TIz6aEMgSOAxFaIVhesEGAhr7WWUKKW1jCTHKpCKITUVhiWM1nKGvOS10WpKjEll79rTTo0eGybrXeD8ruGQfNNr0n0mh964gstPGoY</recordid><startdate>202104</startdate><enddate>202104</enddate><creator>Latif, Abdul</creator><creator>Bibi, Samina</creator><creator>Ali, Sardar</creator><creator>Ammara, Ammara</creator><creator>Ahmad, Manzoor</creator><creator>Khan, Ajmal</creator><creator>Al‐Harrasi, Ahmed</creator><creator>Ullah, Farhat</creator><creator>Ali, Mumtaz</creator><scope>AAYXX</scope><scope>CITATION</scope><orcidid>https://orcid.org/0000-0002-3329-4039</orcidid></search><sort><creationdate>202104</creationdate><title>New multitarget directed benzimidazole‐2‐thiol‐based heterocycles as prospective anti‐radical and anti‐Alzheimer 's agents</title><author>Latif, Abdul ; Bibi, Samina ; Ali, Sardar ; Ammara, Ammara ; Ahmad, Manzoor ; Khan, Ajmal ; Al‐Harrasi, Ahmed ; Ullah, Farhat ; Ali, Mumtaz</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c740-e02e009ef33fb51530d048bb906eb9dc1ce02a7e0539bd3c1419698e462856a73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Latif, Abdul</creatorcontrib><creatorcontrib>Bibi, Samina</creatorcontrib><creatorcontrib>Ali, Sardar</creatorcontrib><creatorcontrib>Ammara, Ammara</creatorcontrib><creatorcontrib>Ahmad, Manzoor</creatorcontrib><creatorcontrib>Khan, Ajmal</creatorcontrib><creatorcontrib>Al‐Harrasi, Ahmed</creatorcontrib><creatorcontrib>Ullah, Farhat</creatorcontrib><creatorcontrib>Ali, Mumtaz</creatorcontrib><collection>CrossRef</collection><jtitle>Drug development research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Latif, Abdul</au><au>Bibi, Samina</au><au>Ali, Sardar</au><au>Ammara, Ammara</au><au>Ahmad, Manzoor</au><au>Khan, Ajmal</au><au>Al‐Harrasi, Ahmed</au><au>Ullah, Farhat</au><au>Ali, Mumtaz</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>New multitarget directed benzimidazole‐2‐thiol‐based heterocycles as prospective anti‐radical and anti‐Alzheimer 's agents</atitle><jtitle>Drug development research</jtitle><date>2021-04</date><risdate>2021</risdate><volume>82</volume><issue>2</issue><spage>207</spage><epage>216</epage><pages>207-216</pages><issn>0272-4391</issn><eissn>1098-2299</eissn><abstract>A series of new heterocycles (
4
–
18
) was synthesized by the structural modification of benzimidazole‐2‐thiol (BT, 2‐MBI). The structures of the synthesized compounds were confirmed with the help of high‐resolution mass spectrometry (HRMS) and
1
HNMR spectroscopy. High inhibitions of the oxidants such as ABTS and DPPH were observed for compounds
9
[IC
50
(s) = 167.4 μM (ABTS), 139.5 μM (DPPH)],
10
[IC
50
(s) = 186.5 μM (ABTS), 155.4 μM (DPPH)],
11
[IC
50
(s) = 286.1 μM (ABTS), 189.1 μM (DPPH)],
12
[IC
50
(s) = 310.8 μM (ABTS), 162.2 μM (DPPH)],
14
[IC
50
(s) = 281.3 μM (ABTS), 205.7 μM (DPPH)],
15
[IC
50
(s) = 284.1 μM (ABTS), 177.3 μM (DPPH)], and
16
[IC
50
(s) = 344.7 μM (ABTS), 270.2 μM (DPPH)] as compared with Ascorbic acid [IC
50
(s) = 340.9 μM (ABTS), 164.3 μM (DPPH)]. The anti‐Alzheimer's activity was performed in vitro against cholinesterase enzymes (AChE, BChE). Compound
11
was able to show significant inhibitions [IC
50
(s) = 121.2 μM (AChE), 38.3 μM (BChE)] as against that of galantamine [IC
50
(s) = 139.4 μM (AChE), 40.3 μM (BChE)]. Compound
14
was found as a very good inhibitor of butyrylcholinesterase (IC
50
= 35.4 μM) as compared with standard galantamine. Molecular docking was further performed to investigate the mechanism of anticholinesterase activity.</abstract><doi>10.1002/ddr.21740</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-3329-4039</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0272-4391 |
| ispartof | Drug development research, 2021-04, Vol.82 (2), p.207-216 |
| issn | 0272-4391 1098-2299 |
| language | eng |
| recordid | cdi_crossref_primary_10_1002_ddr_21740 |
| source | Wiley Online Library All Journals |
| title | New multitarget directed benzimidazole‐2‐thiol‐based heterocycles as prospective anti‐radical and anti‐Alzheimer 's agents |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T08%3A04%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-crossref&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=New%20multitarget%20directed%20benzimidazole%E2%80%902%E2%80%90thiol%E2%80%90based%20heterocycles%20as%20prospective%20anti%E2%80%90radical%20and%20anti%E2%80%90Alzheimer%20's%20agents&rft.jtitle=Drug%20development%20research&rft.au=Latif,%20Abdul&rft.date=2021-04&rft.volume=82&rft.issue=2&rft.spage=207&rft.epage=216&rft.pages=207-216&rft.issn=0272-4391&rft.eissn=1098-2299&rft_id=info:doi/10.1002/ddr.21740&rft_dat=%3Ccrossref%3E10_1002_ddr_21740%3C/crossref%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |